The US FTC announces a multilateral working group to build a new approach to pharmaceutical mergers

Reform of traditional antitrust enforcement and competition law globally has been an on-going discussion amongst enforcers, politicians, advisors, economic experts, and academics. While conversations pertaining to antitrust reforms have been widely centered around resolving the issues presented by Big Tech, the pharmaceutical industry remains a key focus of competition agencies globally. This article will discuss two recent steps enforcement agencies have taken to address competition in the pharmaceutical industry—the recently announced multi-jurisdictional Working Group and the 6(b) Order issued to six health insurance companies by the Federal Trade Commission (FTC). Both working groups and 6(b) Orders are well established tools in the FTC’s tool kit and their use has been increasingly

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Skadden, Arps, Slate, Meagher & Flom (New York)
  • Skadden, Arps, Slate, Meagher & Flom (New York)

Quotation

Karen M. Lent, Kenneth B. Schwartz, The US FTC announces a multilateral working group to build a new approach to pharmaceutical mergers, 16 March 2021, e-Competitions June 2021, Art. N° 100476

Visites 151

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues